Hepatitis News: Breaking Hepatitis News, Comments and Articles.

J&J plans to submit 10 new drugs for approval by 2017

Johnson & Johnson's pharmaceuticals segment plans to submit 10 new product filings for regulatory approval over the next four years. These products are aimed at addressing serious unmet medical needs, such as Hepatitis C, schizophrenia and influe...

J&J plans filing on more than 10 new drugs by 2017

(Reuters) - Johnson & Johnson said on Thursday it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases and schizophrenia, and vaccines for flu, rabies and polio.

UPDATE 1-J&J plans filing on more than 10 new drugs by 2017

May 23 (Reuters) - Johnson & Johnson said on Thursday it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases and schizophrenia, and vaccines for flu, rabies and polio.

Johnson & Johnson plans on more than 10 drugs filed by 2017

May 23 (Reuters) - Johnson & Johnson said on Thursday that it plans to submit more than 10 new products for regulatory approval by 2017, including drugs to treat hepatitis C, immune diseases, and schizophrenia as well as vaccines for flu, rabies and...

The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments

EXTON, Pa., May 23, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, unaided, one in five surveyed gastroenterologists, hepatologists, and infectious disease specialists reported that in the past six months, they have begun warehousing patients (e.g., intentionally delaying treatment) in anti...

The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments

EXTON, Pa. , May 23, 2013 /- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, unaided, one in five surveyed gastroenterologists, hepatologists, and infectious dise...

CannaMed Now Offering Boston Medical Cards: Medical Marijuana Card

CannaMed is now offering Medical Marijuana Consultations in Boston (Framingham). Boston, MA (PRWEB) May 23, 2013 CannaMed is now offering Medical Marijuana Consultations in Boston (Framingham). As per The Initiative Petition for a Law for the Humanitarian Medical Use of Marijuana that passed pursuant to Amendment Article 48 of the Massachusetts Constitution. CannaMed is one of only a few Medical...

AASLD members at forefront to raise awareness of hepatitis B and C

Viral hepatitis is an asymptomatic disease affecting more than 5.3 million Americans. More than 75 percent of those with hepatitis C are unaware they have the virus.

Room For HCV-Focused Start-Ups If The Technology Is Truly Novel

Hepatitis C has been the focus of some of biopharma’s most expensive deals the past couple years. In the wake of the licensing, IPO, and M&A frenzy, not many new start-ups have emerged, but there are a still a few niches to fill if entrepreneur...

Hepatitis Awareness: Bringing Attention to a Silent Epidemic

ALEXANDRIA, Va., May 22, 2013 /PRNewswire/ -- Viral hepatitis is an asymptomatic disease affecting more than 5.3 million Americans. More than 75 percent of those with hepatitis C are unaware they have the virus. Hepatitis B and C Testing and Awareness Day in the U.S. House of Representatives will take place at 10:00 am - 2:00 pm in the Rayburn Foyer of the Rayburn House Office Building in W...

EMA accelerates Gilead HCV drug

Gilead Sciences hopes to launch sofosbuvir for chronic hepatitis C virus (HCV) infection in the first half of 2014 in Europe after the European Medicines Agency ( EMA) accepted the firm's marketing authorization application (MAA) for the drug, and.....

Half Of Hepatitis C Patients Receive Follow-Up Tests

Just half of Americans who have been diagnosed with Hepatitis C receive follow up tests, according to a new CDC report. A majority of patients are baby boomers.

Experts urge baby boomers to get screened for HCV

If you're a baby boomer, you may not know that odds are high that you're carrying the hepatitis C virus, putting yourself at risk for illness that can range from minor to life threatening.

Gilead Sciences' sofosbuvir MAA gets EMA validation

Gilead Sciences, Inc. today announced that the company's Marketing Authorisation Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection, which was submitted to the European...

New Drugs For IBS, Hepatitis C

Research presented at Digestive Disease Week® (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C. An international study holds promising results for patients suffering from IBS-D. In th...

Viral hepatitis: Carjacking HBV therapy

MicroRNAs in liver disease

This Review summarizes current knowledge on the role of different microRNAs (miRNAs) in liver diseases. The functions of the most relevant miRNAs that have specific roles in liver damage, hepatocyte functions, viral hepatitis, alcoholic and nonalcoho...

European Medicines Agency Validates Gilead's Marketing Application for Sofosbuvir for the Treatment of Hepatitis C

-- Once-Daily Sofosbuvir will Receive an Accelerated Assessment by EMA; Designation Granted to New Medicines of Major Public Health Interest -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced...

European Medicines Agency Validates Gilead’s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C

-- Once-Daily Sofosbuvir will Receive an Accelerated Assessment by EMA; Designation Granted to New Medicines of Major Public Health Interest -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Marketing Authorisation Application (MAA) for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for...

Baby Boomers Urged to Get Tested for Hepatitis C Virus

KANSAS CITY, Mo., May 21, 2013 /PRNewswire-USNewswire/ -- If you're a baby boomer, you may not know that odds are high that you're carrying the hepatitis C virus, putting yourself at risk for illness that can range from minor to life threatening. Hepatitis C is a contagious disease affecting primarily the liver, caused by the hepatitis C virus (HCV). The disease can range in severity from a mild...

Idenix Pharmaceuticals' CEO Presents at UBS Global Healthcare Services Conference (Transcript)

Idenix Pharmaceuticals, Inc. (IDIX) UBS Global Healthcare Services Conference Call May 21, 2013 8:00 a.m. ET Executives Ronald Renaud - President and Chief Executive Officer Analysts Matthew Roden - UBS Presentation Matthew Roden - UBS Good morning everyone. I am Matt Roden, biotech analyst here at UBS, and we are pleased to introduce our first speaker of the day. I am pleased and...

Medivir: Positive results from a phase Ia study with MIV-711 for the treatment of skeletal disorders

Single doses of MIV-711 were safe and well tolerated in healthy subjects and displayed linear pharmacokinetics over the investigated dose range (20 – 600 mg) Serum levels of the bone resorption biomarker CTX-I were suppressed in a dose dependent manner) with up to 79% reduction at 24 hours after dose...

EMA validates Gilead’s marketing application for sofosbuvir for the treatment of hepatitis C

Gilead Sciences announced that the company’s MAA for sofosbuvir...

Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

ORLANDO, Fla., May 21, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-experienced genotype 1 chronic hepa...

U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015

ST. LOUIS, May 21, 2013 /PRNewswire/ -- U.S. spending on specialty prescription drugs — those used to treat chronic, complex diseases such as cancer, multiple sclerosis and rheumatoid arthritis — is projected to increase 67 percent by the end of 2015, according to a forecast released today by Express Scripts (NASDAQ: ESRX). (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCR...